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G6PD protects from oxidative damage and
improves healthspan in mice
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Reactive oxygen species (ROS) are constantly generated by cells and ROS-derived damage
contributes to ageing. Protection against oxidative damage largely relies on the reductive
power of NAPDH, whose levels are mostly determined by the enzyme glucose-6-phosphate
dehydrogenase (G6PD). Here, we report a transgenic mouse model with moderate
overexpression of human G6PD under its endogenous promoter. Importantly, G6PD-Tg mice
have higher levels of NADPH, lower levels of ROS-derived damage, and better protection
from ageing-associated functional decline, including extended median lifespan in females. The
G6PD transgene has no effect on tumour development, even after combining with various
tumour-prone genetic alterations. We conclude that a modest increase in G6PD activity
is beneficial for healthspan through increased NADPH levels and protection from the
deleterious effects of ROS.
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eactive oxygen species (ROS) are generated as a result of
normal intracellular metabolism and by the action of
several external agents. ROS function as physiological
signalling molecules that participate in the modulation of
apoptosis, stress responses and proliferation. However, ROS can
have a detrimental side by inflicting damage to macromolecules.
Thus, organisms are endowed with antioxidant mechanisms that
maintain ROS levels below a certain threshold under homoeo-
static conditions1. During organismal ageing, regulation of ROS
and oxidative repair become less efficient, thereby resulting in
increased ROS production and accumulation of ROS-derived
damage. The ‘free radical theory of ageing’ argues that
ROS-derived damage contributes to the functional decline of
organ systems and predisposes to pathologies such as cancer,
cardiovascular and neurodegenerative diseases2,3. In support of
this, transgenic mice with increased expression of antioxidant
enzymes are generally protected from a number of pathologies
and in a few cases they present an increased lifespan4.
Thioredoxins, glutaredoxins and peroxiredoxins constitute a
major antioxidant system that ultimately relies on the reductive
power of NADPH5. NADPH also contributes to the maintenance
of the active form of catalase, another important ROS-detoxifying
enzyme6. Therefore, the homeostatic levels of NADPH
are thought to determine the rate of ROS-derived damage5.
Mammalian cells possess a few enzymes able to produce NADPH
and, among them, glucose-6-phosphate dehydrogenase (G6PD) is
considered the most important one7,8. G6PD catalyses the
rate-limiting step in the pentose phosphate pathway (PPP),
which provides nucleotide precursors for DNA replication, as
well as NADPH reductive power for ROS detoxification and de
novo lipid synthesis. The relevance of G6PD and the PPP in ROS
detoxification is exemplified by the fact that mice deficient in
G6PD have high levels of oxidative damage in the brain9. Also,
human skin cells respond to acute oxidative stress by boosting
their PPP-mediated NADPH production10. Finally, G6PD
overexpression in Drosophila melanogaster protects against
oxidative stress and can extend lifespan11.
Despite the central role of G6PD in antioxidant defence,
nucleotide precursor synthesis and lipid synthesis, the conse-
quences of G6PD overexpression in mammalian physiology have
not been studied. Two points are of particular interest. First,
G6PD may improve ROS detoxification and thereby reduce
ROS-derived damage during ageing. Second, improved ROS
detoxification and enhanced anabolism of nucleotides and lipids
may favour tumoral growth. Here, we address these questions
by generating transgenic mice with moderate ubiquitous over-
expression of human G6PD under the control of its natural
promoter.
Results
Generation of G6PD transgenic mice. For the generation of the
G6PD transgenic mice, we used a large intact genomic fragment
(20.1 Kb) comprising the entire human G6PD gene, including
upstream and downstream regulatory sequences12. In this
manner, we obtained a transgenic mouse line (G6PD-Tg) that
expresses B2-fold levels of total G6PD mRNA (combined
endogenous mouse mRNA and transgenic human mRNA)
relative to wild-type (WT) littermates across all examined
tissues and in mouse embryo fibroblasts (MEFs) (Fig. 1a). This
was accompanied by a similar increase in protein levels (mouse
and human proteins detected with the same antibody) (Fig. 1b;
Supplementary Fig. 1).
The impact of the G6PD-Tg allele was measured first in
erythrocytes, a cell type highly exposed to oxidative damage,
and exclusively dependent on the PPP to obtain NADPH13.
Importantly, erythrocytes from G6PD-Tg mice present a fivefold
increase in G6PD enzymatic activity compared to WT littermates
(Fig. 1c). Elevated G6PD enzymatic activity was also observed in
liver and heart (Fig. 1c). In agreement with the role of G6PD in
the maintenance of the NADPH pools, G6PD-Tg animals had
significantly higher levels of NADPH in liver and brain (Fig. 1d).
In addition to NADPH, the PPP generates nucleotides. In this
regard, uric acid is the major end product of nucleotide
metabolism and, therefore, uric acid levels can be used as a
surrogate measurement of nucleotide metabolism. Interestingly,
G6PD-Tg mice presented higher levels of plasma uric acid than
their littermate controls (Fig. 1e). Finally, we also observed higher
production of lactate in erythrocytes and increased total levels of
lactate in plasma from G6PD-Tg mice, compared with WT
controls (Fig. 1f). This increase in lactate is compatible with an
elevated glycolytic flux, which could be due to the glycolytic
intermediates generated by the PPP14,15. Together, these
observations indicate that G6PD-Tg mice have constitutively
increased levels of PPP activity and thereby higher levels of
NADPH.
We wondered whether the higher NADPH levels observed in
G6PD-Tg cells have a detectable impact in functional assays that
depend on NADPH. For this, we first tested the survival of
G6PD-Tg primary MEFs to diamide, a thiol-oxidant that oxidizes
glutathione (GSH), thereby exhausting the NADPH reservoir16.
In agreement with their elevated levels of G6PD expression,
G6PD-Tg MEFs were more resistant to diamide compared with
control WT MEFs (Fig. 1g). We also tested cell survival
to paraquat, a highly toxic pro-drug whose activation by
NADPH-cytochrome c reductase depends on the levels of
NADPH17. Accordingly, G6PD-Tg MEFs were more sensitive
to paraquat compared with WT MEFs (Fig. 1h). A similar trend
was observed when mice were treated with paraquat, being
G6PD-Tg mice more sensitive than WT mice to paraquat-
induced lethality (Fig. 1i). In summary, two NADPH-dependent
processes (resistance to diamide and sensitivity to paraquat) are
enhanced by moderate G6PD overexpression. Altogether, we
conclude that we have successfully generated a suitable tool to
address the impact of G6PD overexpression and, thereby, higher
NADPH levels in mouse physiology.
Improved healthspan in G6PD-Tg mice. G6PD overexpression
in flies extends longevity11 and based on this, we begun by
studying the lifespan and ageing of G6PD-Tg mice. We followed
cohorts of G6PD-Tg mice, together with their WT littermates,
during their entire lifespan under standard chow diet.
We observed a significant increase in the median lifespan
of G6PD-Tg female mice (3.45 months or 13.7%), but not in
G6PD-Tg males (Fig. 2a,b). No effects were observed in maximal
lifespan in male or female G6PD-Tg mice. After detailed
histopathological analyses of the deceased mice, we could not
observe significant differences in the profile of pathologies
developed by G6PD-Tg mice compared with WT control mice
(Supplementary Fig. 2).
We also wondered whether G6PD overexpression could have
an impact on organismal functional decline during ageing.
For this, a homogeneous cohort of WT and G6PD-Tg mice of
similar ages was used to perform phenotypic experiments.
Ageing-associated obesity is a main risk factor for a number of
diseases, most notably including diabetes18. Interestingly, old
G6PD-Tg animals had a tendency towards lower body weight
compared with their WT littermates (12% reduction in males
and 9% reduction in females), although the differences were
not statistically significant (Fig. 2c; Supplementary Fig. 3a).
In addition, dual energy X-ray absorptiometry (DEXA) analysis
revealed that old G6PD-Tg mice presented a normal lean mass
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and a slight reduction in fat mass, although the latter did not
reach statistical significance (Supplementary Fig. 3b). Glucose
intolerance and insulin resistance are associated to mouse ageing,
and these processes are more pronounced in males compared to
females. Interestingly, 1-year-old G6PD-Tg males were more
glucose tolerant than their WT littermates, and presented
improved insulin sensitivity at 15 min after insulin injection
(Fig. 2d,e). At 6 months of age, G6PD-Tg males were equal to
WT mice regarding glucose tolerance and insulin sensitivity (data
not shown). In the case of females, glucose tolerance and insulin
sensitivity were indistinguishable at one year of age between
transgenic and WT genotypes (Supplementary Fig. 3c,d). We also
performed a complete laboratory animal monitoring experiment
on 1-year-old mice, measuring energy expenditure, food and
water intake and locomotor activity. None of these parameters
were changed between G6PD-Tg animals and their WT
littermates (Supplementary Fig. 3e–h), indicating that the
observed improvements in glucose tolerance and insulin
sensitivity are not due to a significant alteration in energy
expenditure, intake or activity. Finally, we tested neuromuscular
fitness in aged mice using the rotarod test, and we observed a
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Figure 1 | Characterization of the G6PD-Tg mice. (a) Relative G6PD mRNA of the indicated tissues from mice 10–12 weeks old, one male and two females
for the WT group, one male (M) and five females (F) in the Tg group. (b) Levels of G6PD protein in the indicated tissues from 3 to 4-months-old mice and
mouse embryo fibroblasts (MEFs) where each lane corresponds to one individual animal for the tissues (WAT: white adipose tissue; RBC: red blood cells),
or an independent MEF preparation for the MEFs. The anti-G6PD antibody reacts with both the mouse and human G6PD protein. In some tissues (liver,
heart), a second upper band was also detected. ACTIN or GAPDH were used as loading controls. (c) G6PD enzymatic activity in the indicated samples.
(d) Levels of NADPH in the indicated tissues. (e) Uric acid concentration in plasma. (f) Lactate production in isolated erythrocytes (left panel) and total
levels of lactate in plasma (right panel). (g,h) Percentage of cell survival in G6PD-Tg and WT primary MEFs upon treatment with the oxidative stress
inducers diamide (g) and paraquat (h). (i) Survival curve of mice treated with a lethal dose of paraquat. Bars represent the mean±s.e.m. Statistic
significance was assessed using the two-tailed Student’s t-test for all experiments, with the exception of i, where the logrank test was applied: *Po0.05;
**Po0.01; ***Po0.001.
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and a non-significant trend for improvement in G6PD-Tg males
at 1.5–2 years of age (Fig. 2f). In summary, G6PD overexpression
in mice partially protects from ageing-associated functional
decline, which depending on the sex manifests on different
ageing-associated processes, including glucose tolerance, insulin
sensitivity, neuromuscular fitness, and median lifespan.
Cancer susceptibility is not affected in G6PD-Tg mice. G6PD
has been proposed to have pro-oncogenic properties based on its
overexpression in several tumour types and studies with in vitro
cultured cells19–22. In particular, overexpression of G6PD in
murine fibroblasts under the actin promoter is able to
increase their proliferation rate and may induce oncogenic
transformation22. We wondered if this could also be the case in
our G6PD-Tg MEFs, which overexpress G6PD under its natural
promoter. G6PD-Tg MEFs proliferated at the same rate than their
WT controls at different concentrations of serum (Fig. 3a), and
formed the same number of neoplastic foci after co-transduction
of oncogenes E1A and HRasG12V (Fig. 3b) or E6 and HRasG12V
(Fig. 3c). The process of reprogramming of differentiated
cells into induced pluripotent stem cells (iPSC) shares
some similarities with neoplastic transformation and it can
provide a readout of transformability and oncogenic potential23.
Interestingly, G6PD-Tg MEFs formed the same number of iPSC
colonies than WT MEFs upon reprogramming with Oct4, Klf4
and Sox2 (Fig. 3d).
At the organismal level, we did not detect any significant
increase in the incidence of spontaneous cancers in G6PD-Tg
animals (Supplementary Fig. 2). To further investigate in vivo
the possible oncogenic activity of G6PD, we combined the
G6PD-Tg allele with different pro-oncogenic backgrounds. In
particular, p53-null (p53-KO), which develop mostly sarcomas
and T-cell lymphomas24; Atm-null (ATM-KO), which develop
T-cell lymphomas25; MMTV-PyMT (polyoma middle-T
oncoprotein under the mouse mammary tumor virus promoter),
mammary carcinomas26; and Em-Myc, B-cell lymphomas27.
Notably, survival of all these tumour-prone mouse lines was
indistinguishable regardless of the presence of the G6PD-Tg allele
(Fig. 3e–h). Finally, we subjected G6PD-Tg mice and their WT
littermates to 3-methyl-cholantrene (3MC), a potent carcinogen
that induces fibrosarcomas in a p53 and p19Arf-dependent
fashion28,29, and G6PD-Tg mice developed tumors with the
same kinetics as WT controls (Fig. 3i).
All together, we conclude that moderate overexpression of
G6PD under its natural promoter does not result in increased
tumorigenesis.
Lower ROS-derived damage in aged G6PD-Tg mice.
ROS-derived damage increases continuously with ageing30,31 and
some antioxidant manipulations delay ageing4. Based on this, we
hypothesized that increased G6PD expression and activity could
lead to decreased ROS-derived damage. To test this, we first
analysed the expression and activity of G6PD in liver, brain and
muscle from neonates (0–2 days), young (10–35 weeks) and old
(125–143 weeks) G6PD-Tg and WT mice. Expression and activity
of G6PD were increased in the liver and brain of young and old
G6PD-Tg mice (Fig. 4a,b). Higher G6PD activity was also
observed in the muscle from young and old G6PD-Tg mice
(Supplementary Fig. 4a). Of note, G6PD-Tg expression was
slightly higher in females compared to males, which could be due
to the known positive regulation of G6PD expression by
oestrogens32,33. We wondered if G6PD overexpression could
have an impact on the expression of antioxidant genes with
ageing. We observed a modest increase in the mRNA levels of
some antioxidant genes (Cat, Sod1 and Txnrd1) in young female
mice (Supplementary Fig. 4b). However, at old age, all the
examined antioxidant genes showed a global reduction in
expression relative to young mice and no differences were
observed between WT and G6PD-Tg mice regardless of their sex
(Supplementary Fig. 4b). The decrease in expression of
antioxidant enzymes with age had been previously reported in
rodents30 and humans31. Finally, the total protein levels of
several redox catalysts, such as thioredoxins, glutaredoxins and
peroxiredoxins, were not altered in young or old G6PD-Tg mice
(Supplementary Fig. 4c).
To assess the impact of lifelong overexpression of G6PD on
ROS-derived damage, we measured the levels of macromolecular
oxidative damage in young and old mice. Importantly, old
G6PD-Tg male and female mice showed diminished accumula-
tion of DNA oxidation (measured as 8-hydroxyguanosine or





















































































































































Figure 2 | G6PD-Tg mice display improved healthspan. (a,b) Survival curves of female (a) and male (b) mice of the indicated genotypes. (c) Weight of
males during the indicated time. (d,e) GTT (d) and ITT (e) on 1–year-old male mice. Inset, area under the curve (AUC). (f) Rotarod test on 1.5–2-year-old
mice. Bars and dots represent average±s.e.m. Statistical significance was assessed using two-tailed Student’s t-test with the exception of panels a and b,
where logrank test was used: *Po0.05.
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reduced lipid oxidation (measured as malondialdehyde or MDA)
in the liver (Fig. 4e; Supplementary Fig. 5a), but not in the brain
(Supplementary Fig. 5b). No changes were observed in protein
oxidation (measured as carbonylated proteins) in the liver of old
male or female G6PD-Tg mice (Supplementary Fig. 5c,d).
Of note, old G6PD-Tg males, but not females, presented a
small but significant increase in brain protein carbonylation
(Supplementary Fig. 5e,f). In accordance with these findings, and
further supporting the role of G6PD in NADPH-dependent ROS
detoxification, liver from 2-year-old G6PD-Tg female mice
presented an elevated reduced versus oxidized gluthatione ratio
(GSH:GSSG) ratio (Fig. 4f), which is indicative of improved ROS
detoxification34. This increased GSH:GSSG ratio was due to an
elevation in reduced GSH (Fig. 4g), without a detectable change
in oxidized glutathione (GSSG) (Fig. 4h). Since the conversion of
GSSG to GSH (by glutathione reductase) requires NADPH, our
results again indicate that G6PD-Tg animals, by having increased
levels of NADPH, possess a more robust degree of ROS
detoxification, and thus lower accumulation of ROS-derived
damage at old age.
Discussion
Ageing is a complex process driven by multiple sources of
damage, both internal and external. Genetic studies in animal
models have uncovered genes that are able to affect the ageing
process, but their discovery and characterization still remains
challenging, particularly in mammals. Our work uncovers a novel
genetic manipulation that improves some aspects of ageing in
mammals.
G6PD is the rate-limiting enzyme for the PPP, which plays two
important roles in cell physiology: synthesis of nucleotide
precursors, and production of NADPH, which in turn is the
main determinant of the antioxidant capacity of cells. Here, we
have generated transgenic mice with modest (B2-fold) over-
expression of G6PD and we show in vivo that this reflects in
higher levels of NAPDH and in higher production of nucleotide
precursors (measured as uric acid in the blood).
Phenotypically, analyses of G6PD-Tg mice at different ages
have revealed that these mice are partially protected from some
ageing-associated processes. In particular, old G6PD-Tg mice
presented improved glucose tolerance and insulin sensitivity in
males, and improved rotarod function (an indicator of neuro-
muscular fitness) and increased median lifespan in females. These
results are in line with previous overexpression mouse models of
NADPH-dependent ROS-detoxifying enzymes, some of which
present better glucose tolerance or insulin sensitivity (PRX3-Tg or
PRX4-Tg mice), neuroprotection (GPX1-Tg or GRX2-Tg mice),
protection from cardiovascular damage (GPX4-Tg, TRX1-Tg,
GRX1-Tg and GRX2-Tg mice), or extended median lifespan
without increased maximum lifespan (TRX1-Tg mice)4. The
observed improvement in healthspan in G6PD-Tg mice also
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Figure 3 | Cancer susceptibility is not affected in G6PD-Tg mice. (a) Growth curves of primary MEFs at the indicated serum concentrations.
(b,c) Number of neoplastic foci in MEFs transduced with E1a/HRasGV12 (b) or with E6/HRasG12V (c) after 2 weeks. (d) Fold change of reprogramming
efficiency of primary MEFs after transduction with Oct4, Sox2 and Klf4. (e–i) Survival curves of the indicated mouse lines and experiments. (e) p53-
KO;G6PD-WT, n¼ 21, 7 females (F); 14 males (M). p53-KO;G6PD-Tg, n¼ 32, 12F, 20M. (f) ATM-KO;G6PD-WT, n¼ 7, 3F, 4M; ATM-KO;G6PD-Tg, n¼ 16,
6F, 10M. (g) MMTV-PyMT-Tg;G6PD-WT, n¼ 7F; MMTV-PyMT-Tg;G6PD-Tg, n¼ 10F. (h) Em-Myc-Tg;G6PD-WT, n¼ 6, 3F, 3M; Em-Myc-Tg;G6PD-Tg, n¼ 9,
4F, 5M. (i) Survival curve of mice injected intramuscularly with 3MC, G6PD-WT n¼ 9, 1F, 8M; G6PD-Tg n¼ 8M. Bars represent mean±s.e.m. Statistical
significance was determined by the two-tailed Student’s t-test for a–d, and by the logrank test for e–i. None of the differences was statistically significant.
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coincides with observations in flies, where G6PD overexpression
increased protection from ROS and maximum lifespan11.
Of interest, G6PD overexpression has been found in a number
of human cancers, and G6PD has been proposed to be pro-
oncogenic19–22. However, our in vitro and in vivo data indicate
that moderate overexpression of G6PD does not affect tumour
onset in a WT background, nor in many other tumour-prone
backgrounds (p53-null, Atm-null, MMTV-PyMT or Em-Myc). We
conclude that G6PD overexpression in our G6PD-Tg mice has no
impact on tumorigenesis.
Given the importance of NADPH in antioxidant defences, we
also analysed molecular markers of oxidative damage in aged
mice. Importantly, liver and brain from old G6PD-Tg mice, male
and female, presented lower levels of oxidized DNA. In contrast
to this, G6PD-deficient mice have higher levels of oxidized DNA
(ref. 9). G6PD-Tg females also presented decreased lipid
oxidation in the liver. This protection against oxidative
molecular damage was associated to a higher ratio between
reduced and oxidized glutathione in the liver of old mice.
Together, these observations support a mechanistic link
between increased G6PD activity, elevated NADPH and redox
potential, and improved antioxidant protection, and this
could explain the beneficial health effects observed in old
G6PD-Tg mice.
Methods
Generation of transgenic mice. Transgenic mice were generated at the Spanish
National Cancer Research Center (CNIO) at the Transgenic Mice core facility and
are housed at the specific pathogen free barrier areas of the CNIO Animal House
core facility. G6PD-Tg mouse line was generated using a 20 Kb human genomic
DNA construct containing the entire G6PD gene, including 2.5 Kb of upstream
flanking sequence and 2.0 Kb of downstream flanking sequence12. This G6PD
sequence was isolated from the pBluescript vector by NotI digestion and a
0.5 to 1 ngml 1 DNA solution was injected into the pronuclei of F1 hybrids
(C57BL/6JCBA) fertilized oocytes using standard microinjection procedures.
The resulting offspring was analysed for the presence of the transgene by PCR
reaction using primers specific for the human G6PD gene (Forward: 50-AAGAAG
CAGACTGGAGGAGAAG-30 and Reverse: 50-CAGGTTGTCACTCTCAGAAC
AGA-30) and that do not hybridize to the homologous mouse G6pd gene.
One founder capable of transmitting the transgene to the progeny and that
overexpressed G6PD was identified (þ /þ ;tg), abbreviated here as G6PD-Tg. The
founder G6PD-Tg mouse was backcrossed for three generations with pure C57BL6
mice; in this manner, all of the mice used in this study share a genetic background
that is 93.75% C57BL6. All the C57BL6 mice were purchased from Harlan
Laboratories and correspond to the sub-strain C57BL6/J-OlaHsd.
Animal experimentation. Animal experimentation at the CNIO, Madrid, was
performed according to protocols approved by the CNIO-ISCIII Ethics Committee
for Research and Animal Welfare (CEIyBA).
DEXA on 13 females (5 WT and 8 G6PD-Tg) and 14 males (8 WT and 6
G6PD-Tg) of 1 year of age was performed with isofluorane-anesthetized mice in a
Lunar PixiMUS (GEHC) apparatus.
GTT was performed on O/N fasted animals, 11 females (5 WT and 6 G6PD-Tg)
and 14 males (8 WT and 6 G6PD-Tg) of 1 year of age. Mice were injected IP with
2 g kg 1 dextrose (Sigma) dissolved in sterile saline, and blood glucose levels were
measured with Glucocard strips (A. Menarini Diagnosis) at different time points,
while animals were allowed to drink freely.
ITT was performed in non-fasted animals, 13 females (5 WT and 8 G6PD-Tg)
and 14 males (8 WT and 6 G6PD-Tg) of 1 year of age. Mice were injected with
0.75 U kg 1 insulin (Humumil, Lilly), and blood levels were measured with
Glucocard strips (A. Menarini Diagnosis) at different time points, while animals
were allowed to drink freely.
Rotarod test was performed using the Rotarod apparatus (Panlab). Specifically,
21 females (11 WT and 10 G6PD-Tg) of 2 years of age and 13 males (7 WT and 6
G6PD-Tg) of 1.5 years of age were trained with 3 rounds of rotarod tests for 3 days,
and at the 4th day, data from 3 successive experiments were recorded. Final data is
the average of the 3 experiments performed the 4th day.
Complete laboratory animal monitoring system was performed on 13 females
(5 WT and 8 G6PD-Tg) and 14 males (8 WT and 6 G6PD-Tg) of 1 year of age
using the Oxylet apparatus (Panlab-Harvard Apparatus). Briefly, acclimatization of
mice to the measurement cages was performed 3 days before data recording. Room
temperature was constantly kept at 21 C, while running light/dark cycles of 12 h.
Respiratory quotient (RQ) was calculated as RQ¼VCO2/VO2 from volumes of
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Figure 4 | Overexpression of G6PD in vivo protects from oxidative
damage. (a,b) G6PD mRNA expression levels (a) and G6PD activity (b) in
liver (left panels) and brain (right panels) of neonates, young (10–35
weeks) and old (125–143 weeks) female or male mice. For RNA measures:
neonates, n¼ 5 for all groups. Liver: young WT females, n¼ 11; young Tg
females, n¼ 13; old WT females, n¼ 22; old Tg females, n¼ 22; young WT
males, n¼ 12; young Tg males, n¼ 13; old WT males, n¼ 13; old Tg males,
n¼ 11. Brain: young WT females, n¼ 3; young Tg females, n¼ 6; old WT
females, n¼ 15; old Tg females, n¼ 15; young WT males, n¼4; young Tg
males, n¼ 6; old WT males, n¼ 6; old Tg males, n¼ 5. For G6PD activity:
neonates, n¼4 for all groups. Liver: young WT females, n¼ 8; young Tg
females, n¼8; old WT females, n¼4; old Tg females, n¼ 5; young WT
males, n¼4; young Tg males, n¼4; old WT males, n¼ 5; old Tg males,
n¼ 10. Brain: young WT females, n¼ 3; young Tg females, n¼4; old WT
females, n¼4; old Tg females, n¼ 5; young WT males, n¼4; young Tg
males, n¼4; old WT males, n¼ 5; old Tg males, n¼4. (c,d) DNA oxidation
(8-OHdG adducts) in liver (c) or brain (d). (e) Lipid oxidation (MDA
adducts) in liver. (f–h) GSH:GSSG ratio (f) and GSH (g) or GSSG
(h) concentrations were assayed in liver samples from 2-year-old
female mice. Bars represent mean±s.e.m. Statistical significance was
assayed using the two-tailed Student’s t-test: *Po0.05; **Po0.01;
***Po0.001.
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calculated energy expenditure (EE) as EE¼ (3.815þ (1.232RQ))VO2 1.44).
Moreover, we recorded food and water intake and locomotor activity in time
intervals of 20 min during the whole measurement period.
Resistance to paraquat: 14 female (7 WT and 7 G6PD-Tg) and 14 male (7 WT
and 7 G6PD-Tg) mice of 4 to 6 months of age were intraperitoneally injected with
a lethal dose of paraquat (60 mg kg 1) and their survival fraction was scored every
12 h. Experiment was terminated 5 days (120 h) post-paraquat inoculation.
For 3-methyl-cholanthrene (3MC) carcinogenesis, 1 WT female and 16 male
(8 WT and 8 G6PD-Tg) mice of 3 months of age received a single intramuscular
injection at one of the rear legs of a 100 ml solution containing 3MC (Sigma), at a
concentration of 100 mgml 1 and dissolved in sesame oil (Sigma) and the time
point at which tumors reach 1.5 cm maximum diameter was scored. For cancer
susceptibility, G6PD-Tg animals with a genetic background higher than 96.875%
C57BL6 (F4) were crossed with C57BL6 pro-oncogenic mouse strains and cohorts
of animals were followed and sacrificed when showing overt signs of morbidity
according to the Humane End Point criteria. Specifically, G6PD animals were
crossed to p53-null ( / ) animals to generate p53-KO;G6PD-WT (n¼ 21, 7
females (F) and 14 males (M)) and p53-KO;G6PD-Tg (n¼ 32, 12F and 20M)
mouse lines; to Atm heterozygous (þ / ) animals to generate ATM-KO;G6PD-
WT(n¼ 7, 3F and 4M) and ATM-KO;G6PD-Tg (n¼ 16, 6F and 10M) mouse lines;
to MMTV-PyMT-Tg hemizygous transgenic animals to generate MMTV-PyMT-
Tg;G6PD-WT (n¼ 7F) and MMTV-PyMT-Tg;G6PD-Tg (n¼ 10F) mouse lines
and to Em-Myc-Tg hemizygous transgenic animals to generate Em-myc-Tg;G6PD-
WT (n¼ 6, 3F and 3M) and Em-myc-Tg;G6PD-Tg (n¼ 9, 4F and 5M) mouse lines.
Histopathology. Mice were sacrificed when evident signs of morbidity were
observed. A comprehensive collection of tissues were fixed in 10% buffered
formalin O/N at room temperature, included in paraffin and sections were stained
with hematoxilin–eosin. All slides were analysed by an expert pathologist in a blind
manner with regard to the genotype of the mice.
Western blot. Whole-cell extracts were prepared using RIPA buffer containing
proteinase inhibitors, resolved using NuPAGE 4–12% gradient Bis-Tris gels,
transferred to nitrocellulose and hybridized using antibodies against G6PD
(1:1,000; Abcam, ab993), ACTIN (1:10,000; Sigma, A5441), GAPDH (1:10,000;
Sigma, G8795), a-Tubulin (1:1,000; Sta Cruz, sc-8035), Thioredoxin-1 (1:1000; Cell
Signaling, 2429), Thioredoxin-2 (1:1000; Proteintech, 13089-1-AP), Glutaredoxin-1
(1:1000; Abcam, Cab55059), Glutaredoxin-2 (1:1000; Abcam, ab85267), Peroxir-
edoxin-6 polyclonal antibody (1:1000; Abcam ab59543). HRP-coupled secondary
antibodies (1:2,000) were from Dako Denmark A/S. Uncropped images of all the
immunoblots can be found in Supplementary Figs 6 and 7.
RNA analyses. Total RNA from tissues or cells was extracted using TRIZOL
(Life Technologies) followed by RNA cleanup (Qiagen, 74104) and DNase I
treatment (Qiagen) in column. Samples were reverse transcribed using random
priming and Superscript Reverse Transcriptase (Life Technologies), according to
the manufacturer’s instructions. Quantitative real-time PCR was performed using
DNA master SYBR Green I mix (Applied Biosystems) in an ABI PRISM 7700
thermocycler. Quantifications were made applying the DCt method (DCt¼ (Ct of
gene of interestCt of housekeeping)). The G6PD fold expression corresponds to
the sum of the 2(DCt) for the mouse G6PD and human G6PD primers. The
housekeeping gene used for input normalization was b-actin. Primer sequences
are described in Supplementary Table 1.
Cell culture experiments. For viability assays, MEFs were treated with 0.6 mM
diamide for 4 h or 0.4 mM paraquat for 24 h. Cells were then stained with cresyl
violet (Sigma), and cellular viability was determined by measuring the absorbance
at 595 nm.
For MEFs growth curves, 2500 cells were plated in 96-well plates and in
different concentrations of serum (3 and 10%). At 0 (24 h after plating), 2, 4, 6 and
7 days, cells were stained with cresyl violet and cell concentration was determined
by measuring absorbance at 595 nm.
For transformation assays, MEFs were transduced with retroviral vectors
carrying (a) the oncogenes E1A and HRasG12V in the same policistronic construct,
or (b) two lentiviral vectors carrying the oncogenes E6 and HRasG12V, respectively.
After transduction, 5,000 cells (E1A-HRasG12V) or 20,000 cells (E6þHRasG12V)
were plated in P100 plates, and cultured in DMEMþ 10% fetal bovine serum and
penicillin–streptomycin for 2 weeks. Cells were then fixed with formaldehyde at a
final concentration of 6%, stained with Giemsa (Sigma), and foci were counted.
Reprogramming of primary (passage 2–4) MEFs was performed as previously
described35. In brief, retroviral supernatants were produced in HEK-293T cells
(purchased from Invitrogen) (5 106 cells per 100-mm-diameter dish) transfected
with the ecotropic packaging plasmid pCL-Eco (4 mg) together with one of the
following retroviral constructs (4 mg): pMXs-Klf4, pMXs-Sox2 or pMXs-Oct4.
Transfections were performed using Fugene-6 transfection reagent (Roche)
according to the manufacturer’s protocol. Two days later, retroviral supernatants
(10 ml) were collected serially during the subsequent 48 h, at 12-h intervals, each
time adding fresh medium to the cells (10 ml). The recipient MEFs had been seeded
the previous day (2.5 105 cells per 100-mm-diameter dish) and received 1.5 ml of
each of the corresponding retroviral supernatants. This procedure was repeated
every 12 h for 2 days (a total of four additions). After infection was completed,
medium was replaced by complete KnockOut Serum Replacement (KSR) medium,
composed of DMEM (25 mM glucose) supplemented with serum replacement
(KSR, 15%, Invitrogen), leukemia inhibitory factor (LIF) (1,000 U ml 1), non-
essential amino acids, glutamax and b-mercaptoethanol. Cultures were maintained
in the absence of drug selection with daily medium changes. From days 10 to 12
colonies with ES-cell-like morphology became visible and were scored after alkaline
phosphatase staining.
Biochemical measurements. G6PD activity was determined as described
elsewhere36. Briefly, 1,000 ml of glucose-6-phosphate (10 mM final concentration)
in potassium phosphate buffer was added to a cuvette. Then 400 ml of liver or brain
homogenate were introduced. The reaction was initiated by 400 ml of NADP
(0.9 mM final concentration) in buffer. The mixture was inverted and the
absorbance read over 3 min at 340 nm using a spectrophotometer. Protein
concentrations were determined by Bradford’s method with bovine serum
albumin as standard.
NADPH was determined from tissue lysates using the NADPþ /NADPH
quantification kit (BioVision), following manufacturer’s instructions.
Plasma uric acid concentration assessment was carried into a Randox Daytona
automate using a commercial kit (URIC ACID Liquid Mono Reagent,
COLORIMETRIC RX DaytonaTM, Randox, France) according to the
manufacturer’s protocol.
For plasma lactate measurements, blood sample from the abdominal aorta were
collected in Lithium heparin tubes (microvette, SARSTEDT) and centrifuged at
2,000g during 5 min at room temperature according to the manufacturer’s
instructions. Plasma was then collected and stored at  80 C for further analysis.
About 50 ml of plasma was added to a cuvette containing a hydrazine/glycine buffer
with NADþ and lactate dehydrogenase and incubated with for 30 min at 37 C.
NADH formation is measured by the increase in extinction at 340 nM and
corrected by subtracting the value obtained for the reagent blank. Values are
expressed in mM.
Lactate production from erythrocytes was measured according to previous
methods37. Briefly, blood sample from the abdominal aorta were collected in
Lithium heparin tubes (microvette, SARSTEDT) and centrifuged at 1,200g during
5 min at room temperature. Plasma and buffy coat were removed and erythrocytes
were washed 3 times with Krebs–Ringer phosphate buffer containing 0.2 mM
glucose and pH 7.4. Then, erythrocytes were resuspended in the same buffer to
obtain a 40% haematocrit with a final glucose concentration of 5 mM and
incubated during 180 min at 37 C with gentle agitation. The reaction was stopped
by addition of 0.6 N of HClO4. Denatured proteins were sedimented by
centrifugation for 5 min at 10,000g, and the supernatants were used for the lactate
assay using the method previously described. Data are expressed in mmol h 1.
Oxidative DNA damage was measured by 8-hydroxy-20-deoxyguanosine
(8-OHdG) as previously described38. A commercially available enzyme linked
immunoassay (OxiSelect Oxidative DNA Damage ELISA Kit, Cell Biolabs) was
used to measure oxidized DNA in isolated liver and brain DNA samples. DNA was
extracted from liver and brain via the High Pure PCR Template Preparation Kit
(Roche, GmbH, Germany) according to the manufacturer’s protocol. DNA was
only used if it had a minimum 260:280 ratio of 1.8. The assay was performed
following the manufacturer’s directions. Briefly, 50 ml of DNA or 8-OHdG
standards were first added to an 8-OHdG/BSA (bovine serum albumin) conjugate
preabsorbed microplate. After a brief incubation, an anti-8-OHdG monoclonal
antibody was added, followed by an HRP conjugated secondary antibody. The
8-OHdG content in unknown samples is determined by comparison with
predetermined 8-OHdG standard curve. Samples were normalized to the DNA
concentration measured via a plate spectrophotometer for nucleic acids
(Eppendorf, BioPhotometer). All analyses were done in duplicate. Data are
expressed in pg mg 1 of DNA.
Lipids peroxidation determination as malondialdehyde (MDA) in brain and
liver were performed as described elsewhere39. Briefly, this method is based on the
hydrolysis of lipid peroxides and subsequent formation of the adduct thiobarbituric
acid (TBA) and MDA (TBA–MDA2). This adduct is detected by reverse phase
HPLC and quantified at 532 nm (Ultimate 3000 Dionek). The chromatographic
technique was performed in isocratic mobile phase being a mixture of 50 mM
KH2PO4 (pH 6.8) and acetonitrile (70:30)
Oxidative modification of total proteins in liver and brain were assessed by
immunoblot detection of protein carbonyl groups using the ‘OxyBlot’ protein
oxidation kit (Millipore, MA, USA)40. About 20 mg of total protein was loaded onto
gels and electrophoretically separated. Antibody anti-dinitrophenylhydrazone was
purchased from Intergen Company (Purchase, NY,USA). Total protein carbonyls
were quantified with the OxyBlot kit by densitometry of the blotting and of the
Ponceau red staining, followed by finding the ratio between the total density in the
oxyblot and the total density in the Ponceau red staining. Specific proteins were
visualized by using the enhanced chemiluminescence procedure as specified by the
manufacturer (Amersham). Autoradiographic signals were assessed using a BioRad
scanning densitometer.
Determination of GSH and GSSG was carried out using the high-performance
liquid chromatography method with ultraviolet–visible detection, which we
developed to measure GSSG in the presence of a large excess of GSH41. The essence
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of this method consists of minimizing GSH oxidation, which otherwise would
result in a large increase in GSSG. To measure GSH, liver homogenates (0.5 ml)
were treated at 4 C with 0.5 ml ice-cold perchloric acid (12%) containing 2 mM
bathophenanthroline disulfonic acid (BPDS; Sigma Chemical Co.). For GSSG
determination, samples (0.5 ml) were treated, at 4 C, with 0.5 ml ice-cold
perchloric acid (12%) containing 40 mM N-ethylmaleimide (Sigma Chemical Co.,
St Louis, MO, USA), to prevent GSH oxidation, and 2 mM BPDS. Samples were
then centrifuged at 15,000g for 15 min, at 4 C, and the acidic supernatants were
used for total glutathione and GSSG measurements.
Statistical methods. Statistical tests and significances are specified at every
figure legend. Sample collection was always performed using biological replicates
(individual clones in in vitro experiments, different mouse individuals in in vivo
experiments). Samples (cells or mice) were allocated to their experimental groups
according to their predetermined type (cell type or mouse genotype) and therefore
there was no randomization. Except for the pathological analyses, investigators
were not blinded to the experimental groups (cell types or mouse genotypes).
Normal distribution of the samples groups was assessed by the Shapiro–Wilk test.
Equal variances of the samples groups were assessed by the F-test.
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la Generalitat Valenciana"; RS2012-609 Intramural Grant from INCLIVA and EU
Funded CM1001 and FRAILOMIC-HEALTH.2012.2.1.1-2. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Authors contributions
S.N.-P. and P.J.F.-M. performed most of the experiments, contributed to experimental
design, data analysis, discussion and writing; M.C.G.-C., T.B. and A.S.-P. contributed to
experimental work and design, discussion and writing; J.M.F. performed the histo-
pathological analysis; J.V. contributed to experimental design, discussion and writing;
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10894
8 NATURE COMMUNICATIONS | 7:10894 | DOI: 10.1038/ncomms10894 | www.nature.com/naturecommunications
M.S. designed and supervised the study, secured funding, analysed the data, and wrote
the manuscript. All authors discussed the results and commented on the manuscript.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing financial interests: The authors declare no competing financial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
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